We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
- Authors
Kawashima, Yosuke; Harada, Toshiyuki; Fujita, Yuka; Nakagawa, Taku; Watanabe, Kana; Morikawa, Naoto; Takamura, Kei; Kanazawa, Kenya; Kuda, Tomoya; Usui, Kazuhiro; Sekine, Akimasa; Inoue, Akira; Sugawara, Shunichi
- Abstract
Background: A subset analysis of the CA031 trial showed significant improvement in the overall response rate after administration of carboplatin plus weekly albumin-bound paclitaxel compared to carboplatin plus paclitaxel for squamous cell carcinoma of the lung (SQ). We conducted this phase II study to compare carboplatin plus weekly albumin-bound paclitaxel (CnP) to cisplatin plus gemcitabine (CG), a standard regimen for SQ. Methods: Chemotherapy-naïve patients with SQ were randomly assigned to receive cisplatin (80 mg/m2) on day 1 plus gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks or carboplatin (area under the curve: 6 mg/mL/min) on day 1 plus nab-paclitaxel (75 mg/m2) on days 1, 8, and 15 every 3 weeks. The primary endpoint was overall response rate. The secondary endpoints were progression-free survival, overall survival, disease control rate, and toxicity. Results: Between June 2013 and October 2018, 71 patients were enrolled and assigned to either the CG arm (n = 35) or the CnP arm (n = 36) of the study. The overall response rate was 43% [95% confidence interval (CI) 27.3–58.5] in the CG arm and 47% (95% CI 31.7–62.7) in the CnP arm. Although drug combination efficacies did not differ, there were differences in toxicity: hematologic toxicities (leukopenia, neutropenia, and thrombocytopenia) were found mostly in the CG arm, whereas anemia and sensory neuropathy were more common in the CnP arm. Conclusions: CnP had similar response as CG despite being a carboplatin-based regimen and toxicities differed between arms. Regarding ORR, CnP was comparable to CG for SQ.
- Subjects
SQUAMOUS cell carcinoma; CISPLATIN; CARBOPLATIN; LUNG cancer; PACLITAXEL
- Publication
International Journal of Clinical Oncology, 2021, Vol 26, Issue 3, p515
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-020-01828-1